[ad_1]
Modern corona vaccine
In the context of the war in Corona, and a continuation of efforts to come up with promising vaccines to eradicate the deadly virus.
Moderna Pharmaceutical Industries announced Wednesday that it will soon begin trials of its new Corona virus vaccine in children ages 12 to 17, according to the official U.S. clinical trials website.
Moderna plans to conduct her experiments on at least 3,000 children, half of whom will receive two doses of the vaccine, four weeks apart, while the other half will receive doses of placebo.
According to the “New York Times,” Moderna has yet to reveal when the trials will be located, their locations, or even when volunteer intake will begin.
Despite the success of Moderna’s clinical trials in adults, it is still not possible to give the vaccine to children on a large scale until it has been sufficiently tested in them.
The newspaper quoted the consultant for the Centers for Disease Control and Prevention as saying that children have more active immune systems than adults, which can make their reactions stronger, such as fever, muscle and joint pain and fatigue. .
Schaffner cautioned that children can suffer serious side effects, which can cause parents to refrain from returning them for the second dose of the vaccine.
On Monday, Moderna announced the submission of a license application for the emergency use of its COVID-19 vaccine to gain approval from the US Food and Drug Administration (FDA).
Two weeks after announcing that the vaccine’s effectiveness had reached 94.5 percent according to preliminary results, Moderna revealed that 196 participants in the large clinical trial had contracted Covid-19, including 185 people who received a placebo vaccine and 11 of the group that received the actual vaccine, ie. The effectiveness was 94.1 percent.
An FDA advisory committee is supposed to hold a meeting on vaccines on December 17. This can allow, if the vaccine is given the green light, to be distributed in the following days.
Both the German company “Biontech” and the American “Pfizer” had announced that they had achieved an effective vaccine against the Corona virus, with an effective rate of 95 percent.
